Latest Conference Articles

High Response Rates With Rucaparib in Heavily Pretreated Ovarian Cancer

The majority of heavily pretreated patients with high-grade ovarian cancer and germline or somatic BRCA mutations showed a durable response to rucaparib.

Neoadjuvant Anti-PD-1 Therapy Active in NSCLC

Almost 40% of patients with resected early-stage non–small cell lung cancer had evidence of tumor regression following neoadjuvant treatment with nivolumab (Opdivo) in a preliminary clinical trial.

Thousands of Melanoma Patients in Europe Not Receiving Novel Agents

Over one-fourth of patients with metastatic melanoma in Europe do not have access to groundbreaking therapies that could extend their lives.

Dr. George Somlo on Advances in Multiple Myeloma

Dr. George Somlo, MD, medical oncologist, City of Hope, discusses recent highlights in multiple myeloma.

Dr. William Wierda on Role for Ibrutinib in Frontline CLL

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discuses which chronic lymphocytic leukemia patients may benefit from ibrutinib frontline therapy and questions that remain after the RESONATE-2 trial.

Approved Myeloma Agents Rapidly Incorporated Into NCCN Guidelines

There have been 10 agents approved over the last 12 years for the treatment of patients with multiple myeloma, and pivotal data for each agent has supported rapid inclusion into the NCCN treatment algorithms.

Triplet Therapy, ASCT Frontline Standard for Multiple Myeloma

The preferred primary therapy for patients with multiple myeloma is induction therapy with a triplet regimen followed by autologous stem cell transplantation, consolidation, and maintenance.

Ibrutinib or FCR: Wierda Discusses First-Line Options for CLL

There has been some debate over what should be the standard frontline treatment for patients with chronic lymphocytic leukemia: ibrutinib or chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab.

Dr. Thomas LeBlanc on Patient Shared Decision-Making in Hematologic Malignancies

Thomas LeBlanc, MD, assistant professor of medicine, Duke Cancer Institute, discusses why it is important to include patients in the decision-making process for the treatment of hematologic malignancies.

Dr. Steven Coutre on Frontline Treatment Decisions in CLL

​Steven Coutre, MD, professor of medicine (hematology) at Stanford University Medical Center, discusses considerations when selecting between oral therapies like ibrutinib and chemoimmunotherapy for first-line treatment of chronic lymphocytic leukemia (CLL).

Novel Agents Hold Significant Promise in Treatment of AML

Jessica K. Altman, MD, discussed the potential of agents poised to transform the landscape of acute myeloid leukemia.

Mesa Maps Out Present and Future of Myelofibrosis Care

Ruben Mesa, MD, discussed the latest NCCN treatment guidelines for myelofibrosis and emerging treatments in the field.

Incorporating Generic Imatinib Into Frontline Treatment for CML

As generic imatinib enters the market, new questions focus on a renewed role for the agent in conjunction with second-generation TKIs.

Dr. Jerald Radich on Impact of Generic Imatinib in CML

​Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses the impact of the approval of generic imatinib in chronic myelogenous leukemia (CML).

Dr. Ruben Mesa on New NCCN Guidelines for MPNs

Ruben Mesa, MD chair, hematology Mayo Clinic, MPN, discusses the new National Comprehensive Cancer Network (NCCN) guidelines for myeloproliferative neoplasms (MPN). Ruben Mesa, MD chair, hematology Mayo Clinic, MPN, discusses the new National Comprehensive Cancer Network (NCCN) guidelines for myeloproliferative neoplasms (MPN).

Dr. El-Khoueiry on the Rationale for Evaluating Nivolumab in Advanced HCC

Anthony B. El-Khoueiry, MD, associate professor of Clinical Medicine, USC Norris Comprehensive Cancer Center, discusses the rationale for evaluating nivolumab in advanced hepatocellular carcinoma (HCC).

Dr. Yang on NASH-Associated HCC and Cirrhosis in Diagnosis of Liver Cancer

Ju Dong Yang, MD, MSc, discusses patients with nonalcoholic steatohepatitis (NASH)-associated hepatocellular carcinoma (HCC) who present without cirrhosis at the time of diagnosis of liver cancer.

Conflicting Evidence Surfaces on Anti-HCV Drugs for Liver Cancer

A new generation of drugs has proved highly effective against the hepatitis C virus but there is conflicting evidence about whether the therapies promote cancer recurrence in infected patients with hepatocellular carcinoma who already have responded to curative treatment.

Expert Describes Potential Therapeutic Vaccine for Advanced HCC

Ghassan K. Abou-Alfa, MD, discusses research into the use of the immunotherapeutic vaccinia virus Pexa-Vec as a frontline treatment for advanced hepatocellular carcinoma.

New Roles May Evolve for Competing Embolization Techniques in HCC

Two competing methods of delivering locoregional therapy to patients with hepatocellular carcinoma both have advantages and may be most successful in subgroups of individuals with intermediate-stage disease.

Dr. Do on the Assessment of Tumor Response in Liver Cancer

Richard Kinh Gian Do, MD, PhD, radiologist, Memorial Sloan Kettering Cancer Center, discusses the assessment of tumor response in liver cancer.

Dr. Yao on the Milan Criteria in Liver Cancer

Francis Yao, MD, professor of Clinical Medicine and Surgery, medical director of the Liver Transplant Program at UCSF Medical Center, discusses the Milan criteria in liver cancer.

Large Analysis Sheds Light on Risk Factors for Non-Cirrhotic NASH-Associated HCC

About one quarter of patients with nonalcoholic steatohepatitis-associated hepatocellular carcinoma present without cirrhosis at diagnosis, suggesting a crucial subset of patients for future research with implications for HCC screening and surveillance.

Nivolumab Maintains Positive Results in Latest HCC Findings

Nivolumab continues to post durable responses in patients with advanced hepatocellular carcinoma regardless of whether they had hepatitis B or C or whether they had received prior treatment with sorafenib.

Regorafenib Moves Ahead of Field With Success in Advanced HCC

After 9 years of failed trials for once-promising drugs, regorafenib (Stivarga) has emerged as the clear choice for second-line therapy in advanced hepatocellular carcinoma after demonstrating survival improvements for patients whose disease has progressed after systemic treatment.

Dr. Finn on Finding a Biomarker for Patients With HCC

Richard S. Finn, MD, an associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses the challenges with determing a biomarker for patients with hepatocellular carcinoma (HCC) in an interview during the 10th Annual Conference of the International Liver Cancer Association (ILCA) in Vancouver, Canada. Finn is the current ILCA president.

Dr. Sherman on Screening Obstacles in Liver Cancer

Morris Sherman, MD, PhD, professor of Medicine at University of Toronto, discusses the issues oncologists face with screening patients for hepatocellular carcinoma (HCC) in an interview during the 10th International Liver Cancer Association (ILCA) Annual Conference.

Regorafenib Poised as Second-Line Standard of Care in HCC

Although regorafenib is not currently approved, Morris Sherman, MD, PhD, already views the agent as the standard second-line therapy, with hopes for moving the agent into the frontline setting.

Early Signals Positive for Immunotherapy Plus Standard Therapy in HCC

Early evidence suggests that the combination of locoregional therapy with an immune checkpoint inhibitor is a safe and effective strategy to pursue for patients with advanced hepatocellular carcinoma.

Dr. Zhu on Optimal Second-Line Treatment for Patients With HCC

Andrew X. Zhu, MD, PhD, professor of Medicine, Harvard Medical School, director of Liver Cancer Research, Medicine, Massachusetts General Hospital, discusses the possibility of an optimal second-line treatment for all patients with hepatocellular carcinoma (HCC).